American Society of Addiciton Medicine
Oct 12, 2022 Reporting from Rockville, MD
Substance Use and Substance Use Disorder Among Pregnant and Postpartum People
Oct 12, 2022
ASAM strongly supports reforms to reverse the punitive approach taken to substance use and SUD during and after pregnancy and respond to the shared interests of the parent-newborn dyad by providing ethical, equitable, and accessible, evidence-based care.

Substance Use and Substance Use Disorder Among Pregnant and Postpartum People.Substring(0, maxlength)

American Society of Addictin Medicine


Substance Use and Substance Use Disorder Among Pregnant and Postpartum People


The American Society of Addiction Medicine (ASAM) is deeply committed to the health and well-being of pregnant and postpartum people, their families, and communities. This includes advocating for the prevention and treatment of substance use-related harms throughout the reproductive years, with a focus on the perinatal period. Substance use disorder (SUD) is a stigmatized medical condition, and poorly understood for pregnant and postpartum people, who face discrimination accessing care and treatment.1,2 In areas most affected by the opioid crisis, opioid-involved pregnancies may include as many as 6 percent of childbirths.3

ASAM strongly supports reforms to reverse the punitive approach taken to substance use and SUD during and after pregnancy and respond to the shared interests of the parent-newborn dyad by providing ethical, equitable, and accessible, evidence-based care.4–6 Federal and state systems, healthcare institutions, and clinicians too often conflate substance use with SUD and stigmatize and equate a person with SUD as “unfit to parent" or “criminal”.7 As a result of the punitive approach that has permeated American public policy and practices, people who use substances while pregnant are deterred or delayed from seeking care because of fear of detection, prosecution, and punishment,8 and the rate of child protection system [*] involvement attributed to perinatal or parental substance use has doubled in recent years.9

Potential risks to a child growing up in a home with ongoing substance use can include risks of co-sleeping injuries while intoxicated,10 unintentional ingestions,11 disruption of parenting abilities due to substance use,12 and witnessing parental overdose.13 However, children impacted by family separation have worse long-term outcomes in areas including education, employment, income, housing, health, substance use, and involvement with the criminal legal system, compared to their peers in the general population.14 Furthermore, child removal is associated with return to substance use among the affected parent15 (though the directionality cannot be implied based on currently available research), 16 parental overdose, and higher rates of parental post-traumatic stress disorder (PTSD).17,18

Punitive policies and practices are disproportionately applied to and disparately affect pregnant and postpartum people of color. Despite similar rates of substance use19 and professional medical society recommendations that screening for substance use be universal,20 Black parents and their newborns are 1.5 times more likely to be tested for substances as compared to non-Black parents.21 Black parents and their newborns are also 4 to 10 times more likely than White parents and their newborns to be reported to the child protection system at delivery.22,23 Black and Native American children are overrepresented in foster care at 2 to 11 times the rate of White children in the setting of parental substance use.1,5,24,25 Disparities in addiction care received by people of color have been documented in other ASAM statements6 and may be even more pronounced for people of color during pregnancy,26 although this area is understudied.27 For example, pregnant persons of color receive significantly lower doses of methadone at the time of delivery compared to their White counterparts.28 These disparities occur in an environment where structural racism has contributed to a maternal mortality rate that is 2.9 times higher for non-Hispanic Black people than for White people.29,30

Unique to the perinatal period, use of toxicology testing can have serious legal and social consequences for pregnant and postpartum people.31 When applied, toxicology testing should help clinicians manage addiction treatment or guide clinical management. Despite clear professional society recommendations that toxicology testing requires explicit consent—ASAM’s guidance states “pregnant women should provide explicit written consent for drug testing including during labor and delivery,”32—testing is often done without informing patients of the risks and benefits of testing and without obtaining consent.33 In addition, the information obtained from presumptive toxicology testing is limited by binary results and false positive results.31 Reliance on toxicology test results risks inaccurately equating all substance use with SUD, as substance use exists on a continuum, including, light, moderate, risky, and uncontrolled use behaviors, and may not be associated with SUD. Further, equating a positive toxicology test with child abuse or neglect is scientifically inaccurate and inappropriate, and can lead to an unnecessarily punitive approach, which harms clinician-patient trust and persons’ engagement with healthcare services.34,35

The federal Child Abuse Prevention and Treatment Act (CAPTA) is legislation that emerged in parallel with 1970s American drug policy.36,37 CAPTA provides funds to states to mitigate child abuse and neglect.38 To receive these funds, states must implement:

“…policies and procedures (including appropriate referrals to child protection service [CPS] systems and for other appropriate services) to address the needs of infants born and identified as being affected by substance abuse or withdrawal symptoms resulting from prenatal drug exposure, or a Fetal Alcohol Spectrum Disorder, including a requirement that health care providers involved in the delivery or care of such infants notify the child protective services system of the occurrence of such condition of such infants…”39

The legislation requires plans of safe care[†] be provided for infants affected by withdrawal symptoms from prenatal substance exposure and their caregivers.40

CAPTA’s overall approach and the lack of a definition of “affected by”41 in the statute has led to significant variation in how states, counties, and health care institutions implement its requirements. While CAPTA does not establish a definition of child abuse or neglect under federal law, require toxicology testing in pregnancy, or define a positive toxicology test as per se evidence of civil child abuse or neglect, many states have interpreted it in this way. 38,42 CAPTA does not mandate clinicians to notify CPS of all detected substance exposures, nor does it require prosecution for any illegal action for non-prescribed substance use.38

Most CAPTA funds are spent on maintaining children outside their home, only a small percentage of federal and state/local child protection system funds are spent on substance use prevention or programs that preserve or give financial assistance to families.43 Additionally, CAPTA’s reference to “withdrawal symptoms” is problematic, because some states have interpreted it as inclusive of legally-prescribed opioid agonist medications, an evidence-based treatment for opioid use disorder (OUD).41

The wider misunderstanding of CAPTA and its requirements has been compounded by restrictive and inequitable hospital policies. Many hospitals apply a series of unnecessary restrictions after birth when faced with a positive maternal or infant toxicology test result. These restrictions may result in a separation of the parent-newborn dyad and thus limit the implementation of evidence-based practices such as rooming-in, breast/chestfeeding, and skin-to-skin bonding.44 Hospitals may also implement inequitable surveillance policies after substances have been detected that do not allow perinatal patients to leave inpatient units, have unsupervised visitors (including spouses and other support persons),44 and subjects them to punitive room searches, which can lead to arrests.45

Among pregnant and postpartum people with OUD, opioid agonist medications increase engagement in prenatal and addiction care and improve parental and child outcomes.46 Methadone or buprenorphine remains a standard of care for OUD treatment during pregnancy, and medication doses often require titration during and after pregnancy.47 Methadone and buprenorphine are compatible with breastfeeding, which has been shown to reduce the severity and duration of neonatal abstinence syndrome (NAS), also known as neonatal opioid withdrawal syndrome.4 Pregnant and postpartum people receiving opioid agonist medications for OUD face unique challenges, including limited medication availability, child protection system agency professionals’ misunderstanding of those medications and possible interference in related clinical decisions, and inadequate interaction between the child protection system and clinicians.48

Harm reduction approaches are appropriate throughout the life cycle, including during pregnancy.49 These include access to pregnancy tests and contraception, take-home naloxone, syringe access, and use of “pump and dump” breastfeeding strategies to limit an infant’s exposure to substances.50 The use of harm reduction approaches may reduce poor obstetrical outcomes and parental mortality.51 Support provided through doula care improves maternal health equity; 52 pregnant and postpartum people with OUD who engaged with doula services perceived increased support and reduced stigma by health care providers.53 In addition, paraprofessional-delivered home-visiting programs for parents and children, such as the Family Spirit intervention, improve outcomes and reduce health disparities, including reduced substance use risk.54,55

Only 23% of SUD treatment facilities in 2018 offered programs specifically designed to support pregnant and postpartum people.56 High rates of trauma and intimate partner violence (IPV) are reported by women with SUD; trauma-informed programming is necessary to support women in SUD treatment, in addition to family-friendly treatment.46,57,58 Among adults with unmet SUD treatment needs, parents with a child living at home were three times more likely to report treatment access barriers and four times more likely to specifically report stigma as a barrier to treatment compared to adults without a child at home.57 Many clinicians (both obstetric and addiction medicine) have not received sufficient training in caring for pregnant people with SUD, resulting in insufficient access for pregnant people, especially when they need treatment with addiction medications,59,60 or on caring for people experiencing trauma and IPV.

Treatment discontinuation and overdose deaths are particularly high in the postpartum period.1,61,62 These poor outcomes are exacerbated by the loss of insurance coverage that many people face after giving birth, as Medicaid coverage provided during the pregnancy period traditionally expires 60 days after birth.63 Access to childcare can be a barrier to treatment engagement in the post-partum period, and only 5.5 percent of specialty treatment facilities provided childcare services for patients in 2020.64 Recovery housing for pregnant people is very limited, and few recovery homes will allow people to care for their children on premises.

American drug policy’s criminalization of certain substance use has contributed to the highest rate of incarceration of women among nations; women of color bear the disproportionate burden of this response.65 Pregnant people who are incarcerated are routinely shackled while in labor,66 and often face difficulties in accessing SUD treatment. Although federal courts have granted injunctive relief to plaintiffs from inflexible policies that deny access to medically necessary treatment, including methadone and buprenorphine for OUD during incarceration—given likely violations of the Americans with Disabilities Act (ADA) and/or the Eighth Amendment to the U.S. Constitution’s prohibition of cruel and unusual punishment,67 lack of access to opioid agonist medications for OUD continue to be a challenge in many carceral settings.67–71 One survey found 60 percent of U.S. jails reported continuing opioid agonist medication for OUD for pregnant people who had received such treatment before incarceration, but only 32 percent of jails started methadone or buprenorphine during pregnancy, and most discontinued opioid agonist medications for OUD during the postpartum period.72

ASAM recognizes that the decision in Dobbs v. Jackson Women’s Health Organization to overturn Roe v. Wade will bear a disproportionate burden on pregnant people who use substances.73 In one estimation, 86 percent of pregnant people who used substances had unintended pregnancies.74 The long-standing history of legislative interference with patient-clinician relationships involving patients’ substance use,6,19 and some states’ effective criminalization of substance use while pregnant or postpartum75 has resulted in grave, disproportionate, and inequitable harm, especially to pregnant and postpartum people of color.76 Further, where abortion bans have been enacted, they will likely intensify disparities in maternal mortality rates30 and create even more coercive conditions for pregnant people who enter jail or prison.77,78 In this rapidly evolving situation, ASAM reiterates that clinicians and patients must be able to make clinical decisions without legislative interference, and pregnant people must have access to life-saving medical care. 


The American Society of Addiction Medicine recommends:

Prevention, Screening, and Toxicology Testing

  1. Addiction medicine professionals should screen all people of reproductive age for pregnancy intention, and either provide contraception if desired or refer for comprehensive family planning.
  2. Addiction medicine and reproductive health professionals should work toward co-location and integration of services, including services for trauma and IPV.
  3. All pregnant people should be screened with a validated instrument by their prenatal clinician to identify who may need an assessment for SUD.79 Prenatal providers should use motivational interviewing techniques, offer medication initiation, and/or discuss referral to licensed SUD treatment services if SUD is diagnosed.1
  4. Toxicology testing during the perinatal period should be standardized in hospital policies, be used only when clinical indications suggest it is necessary, be part of a clear plan outlined by the clinician (e.g., how will the result change clinical care?), and—outside of emergency situations—obtained with informed, written32 consent to ensure risks and benefits have been reviewed given the unique legal and social consequences of testing for pregnant and postpartum people. Both clinician and patient should have clarity as to the goal of testing, who will have access to the results, and the possible ramifications of a positive test. Patients have the right of refusal and refusing a toxicology test should neither be seen as indication of use nor detract from clinical care.
  5. A positive screening toxicology test result should be discussed with the patient, and a definitive test should be utilized if the patient’s self-report is not consistent with the presumptive test.
  6. Clinicians should not interpret a positive toxicology test result as determinative of a SUD. A positive toxicology test should result in: a) an increase in the intensity of an addiction treatment plan for patients with a SUD, b) evidence-based early intervention, and c) implementation of service-needs matching41 programs.
  7. Parents should be made aware of toxicology testing of infants, and whenever possible, parental permission should be obtained. Infant meconium, umbilical cord, and cord blood testing often takes 5-7 days to result, lack clinical utility in guiding the management of hospitalized infants, and are not recommended.
  8. Health care systems and hospitals should rigorously evaluate their use and applications of toxicology testing in pregnant and postpartum persons, and neonates, and examine the consequences of sharing the results of such testing outside the health care system; evaluation of such policy should be stratified by race and ethnicity. Policies that result in inequities in practice should be removed; areas where a lack of policy exists and results in inequities in practice should be addressed and rectified.

Federal and State Policy Changes and Reimagining Support

  1. States with legislation defining in-utero substance exposure as child abuse or neglect should eliminate such language. This legislative effort should be informed by public health professionals, medical professional societies, substance use prevention services, child protection agencies, and people with lived experience in joint efforts with champion legislators.
  2. The federal government, through CAPTA revisions and strategic guidance from federal agencies, should incentivize states to implement non-punitive, evidence-based, public health-driven approaches for SUD in pregnant and postpartum people.
    1. A rigorous evaluation of CAPTA strategies should include linked parent-child health data to assess if the legislation is achieving its goal of improving child outcomes.41
    2. Federal agencies should issue guidance with particular attention to how states should define the term “affected by,”80 with clarification that addiction medications, including medications for OUD, are neither considered “prenatal drug exposure” nor should be included under any perceived CAPTA requirements. Any reauthorization of CAPTA should also include such clarification.
  3. Jurisdictions and institutions should remove policies and statutes that may deter pregnant people from seeking care, including mandates to report pregnant or postpartum people to child protection systems or other governmental agencies on the sole basis of substance use or SUD.
  4. Child protection system agencies should not use evidence of substance use to implement sanctions on parents, especially child removal. Such sanctions should only be made when other risk factors or harms have been assessed or identified, and there is objective evidence of abuse, neglect, or other danger to the child.
  5. Jurisdictions should fund programs that focus on substance use prevention, treatment, perinatal care, and recovery supports that are culturally resonant, gender responsive, and trauma-informed, and include wrap around services for pregnant and postpartum people.
  6. Federal and state agencies should fund the provision of social services and financial support to families in need.
    1. Social service benefits and financial support should not be made contingent on toxicology testing of parents.
    2. Federal and state agencies should prioritize funding for programs with demonstrated effectiveness, such as harm reduction programs that provide doula or paraprofessional-delivered home-visiting interventions for parents and children that reduce health disparities and risk of substance use,54,55 and integrated services addressing trauma and IPV.81 New interventions should be rigorously evaluated to consider both intended and unintended outcomes.
    3. Federal and state policy should promote paid family and medical leave, thus allowing parents to fulfill caregiving responsibilities and engage in treatment services without having to forgo paid employment.

Hospital Practices Related to Substance Use

  1. Hospitals should eliminate restrictive and inequitable policies that separate the parental-newborn dyad, limit the implementation of evidence-based practices, restrict patient movement or visitation, and allow for punitive room searches.
  2. Hospitals should implement policies that prioritize the shared interests of the parental-newborn dyad. This includes a) coordination and communication—prior to active labor—among anesthesiology, neonatology, labor, delivery, and pediatric staff, and b) facilitating extended hospital stays for birthing parent when a neonate is being monitored or treated for withdrawal symptoms.
  3. Hospitals should train staff that care for the parental-newborn dyad in the delivery of trauma-informed, respectful, comprehensive care that is patient-centered and tailored to whole person support. 

Approach to Treatment in Peripartum Period

  1. Pregnant and postpartum people who are stable on medication should be maintained on that medication unless there is a clear clinical rationale for discontinuation or due to patient preference.
  2. Treatment decisions should be made collaboratively between a patient and their healthcare provider. Neither child protective services nor judges should make specific treatment recommendations or mandate or prohibit any particular type of treatment or peer support, but instead should know how to help patients connect with local, licensed SUD treatment providers.
  3. Clinicians should make concerted efforts to communicate with social services professionals about the safety, efficacy, and importance of treatment with medications for pregnant and postpartum people with OUD.
  4. Clinical protocols that result in racial inequities in treatment delivery—such as methadone dosage and buprenorphine access—should be identified and rectified.
  5. Barriers to OUD treatment access and retention, including complex intake procedures, access to transportation, and childcare assistance, should be addressed.

Treatment, Harm Reduction, and Recovery Supports

  1. SUD treatment services, residential treatment facilities, clinicians, and harm reduction programs should include reproductive health services, including family planning, contraception services, and pregnancy testing.
  2. Peripartum people should be given priority access to SUD treatment.
  3. Payment models need to ensure that SUD treatment providers can meet the specific needs of pregnant and postpartum people and their families. Such services include but are not limited to: the management of co-occurring mental health conditions, childcare, transportation, housing, nutrition, parenting skills classes, IPV counseling, and encouragement of breast/chestfeeding.  
  4. States should expand Medicaid and the Children’s Health Insurance Program (CHIP) to provide 12 months of coverage for postpartum care under the American Rescue Plan Act.82 States that have not expanded Medicaid as offered under the Affordable Care Act should do so.
  5. State Medicaid programs should reimburse for the full range of prevention and treatment services during pregnancy, including screening, brief intervention, and referral to treatment (SBIRT), and IPV assessment and referral.
  6. Residential treatment and recovery housing facilities should provide affordable, family housing that permits children to live on the premises with a parent receiving treatment or who is in recovery.83
  7. Clinicians should provide counseling regarding harm reduction strategies during and after pregnancy, including approaches to continue breastfeeding safely.
  8. Clinics and hospitals should develop policies to ensure that overdose and suicide prevention is consistently offered, that naloxone kits are prescribed or dispensed, and SUD follow-up is arranged within 48 hours post-hospital discharge.
  9. Harm reduction programs that provide doula, peer support services, or paraprofessional-delivered home-visiting interventions for parents and children should be further studied and those with demonstrated effectiveness for improving health equity should be replicated.

Medical Education

  1. Medical education at all levels should include culturally appropriate education in the treatment and management of SUD during pregnancy and delivery, and the management of NAS; training in universal SUD screening methods, motivational interviewing, SBIRT, and training on responding to IPV. Concurrently, education on harm reduction approaches and the racist history of American drug policy should be taught.
  2. Prenatal providers should be trained to care for pregnant people with SUD, including the use of methadone and buprenorphine for OUD. The American College of Graduate Medical Education program requirements should be updated to state this explicitly.84
  3. State perinatal collaboratives should train and disseminate information to prenatal and pediatric clinicians related to state and child protection system reporting/notification  laws and policies.85,86

Pregnant and Postpartum People Who are Incarcerated

  1. The use of shackles during delivery should not be permitted; policies mandating the use of shackles or handcuffs should be eliminated.
  2. Policies should support rooming-in and breastfeeding while the birthing parent is in the hospital. Telephone privileges while in the hospital should be no more restrictive than while in jail or prison.
  3. Pregnant and postpartum people with SUD who are incarcerated should be able to access addiction medications, whether initiating or continuing a medication. Pregnant people with SUD who are incarcerated and in labor should be brought for appropriate medical care and permitted to continue addiction medications postpartum.
  4. Policies should permit breast/chestfeeding/breast-pumping for postpartum people who are incarcerated.87 

Protecting People’s Bodily Autonomy

  1. It is a critical time for advocates—including clinicians—to unite in opposition to legislative interference with the patient-clinician relationship, such as abortion bans,88 and policies that reduce or eliminate access to voluntary, evidence-based, and in many cases, life-saving medical treatment.


Adopted by the ASAM Board of Directors October 2, 2022.

This policy statement is endorsed by the American College of Academic Addiction Medicine and the American Osteopathic Academy of Addiction Medicine.

This policy statement is supported by the American Academy of Family Physicians.





  1. Smid MC, Terplan M. What Obstetrician–Gynecologists Should Know About Substance Use Disorders in the Perinatal Period. Obstet Gynecol. 2022;139(2):317-337. doi:10.1097/AOG.0000000000004657
  2. Weber A, Miskle B, Lynch A, Arndt S, Acion L. Substance Use in Pregnancy: Identifying Stigma and Improving Care. Subst Abuse Rehabil. 2021;12:105-121. doi:10.2147/SAR.S319180
  3. Haight SC. Opioid Use Disorder Documented at Delivery Hospitalization — United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2018;67. doi:10.15585/mmwr.mm6731a1
  4. Jilani SM, Jones HE, Grossman M, et al. Standardizing the Clinical Definition of Opioid Withdrawal in the Neonate. J Pediatr. 2022;243:33-39.e1. doi:10.1016/j.jpeds.2021.12.021
  5. Sangoi L. “Whatever They Do, I’m her Comfort, I’m her Protector": A Report on the Child Welfare and Foster System by Movement for Family Power. Published online June 23, 2020. Accessed July 13, 2022.
  6. American Society of Addiction Medicine. Public Policy Statement on Advancing Racial Justice in Health Care through Addiction Medicine. Default. Published July 28, 2022. Accessed August 1, 2022.
  7. Terplan M, Kennedy-Hendricks A, Chisolm MS. Prenatal Substance Use: Exploring Assumptions of Maternal Unfitness. Subst Abuse Res Treat. 2015;9(Suppl 2):1-4. doi:10.4137/SART.S23328
  8. Austin AE, Naumann RB, Simmons E. Association of State Child Abuse Policies and Mandated Reporting Policies With Prenatal and Postpartum Care Among Women Who Engaged in Substance Use During Pregnancy. JAMA Pediatr. Published online September 19, 2022. doi:10.1001/jamapediatrics.2022.3396
  9. Meinhofer A, Angleró-Díaz Y. Trends in Foster Care Entry Among Children Removed From Their Homes Because of Parental Drug Use, 2000 to 2017. JAMA Pediatr. 2019;173(9):881-883. doi:10.1001/jamapediatrics.2019.1738
  10. Blair PS, Sidebotham P, Evason-Coombe C, Edmonds M, Heckstall-Smith EMA, Fleming P. Hazardous cosleeping environments and risk factors amenable to change: case-control study of SIDS in south west England. The BMJ. 2009;339:b3666. doi:10.1136/bmj.b3666
  11. Auger N, Chadi N, Low N, Ayoub A, Lo E, Luu TM. Maternal Substance Use Disorders and Accidental Drug Poisonings in Children. Am J Prev Med. 2022;62(3):360-366. doi:10.1016/j.amepre.2021.09.007
  12. Department of Health and Human Services. Effects of Substance Abuse on Behavior and Parenting.
  13. Winstanley EL, Stover AN. The Impact of the Opioid Epidemic on Children and Adolescents. Clin Ther. 2019;41(9):1655-1662. doi:10.1016/j.clinthera.2019.06.003
  14. Gypen L, Vanderfaeillie J, De Maeyer S, Belenger L, Van Holen F. Outcomes of children who grew up in foster care: Systematic-review. Child Youth Serv Rev. 2017;76:74-83. doi:10.1016/j.childyouth.2017.02.035
  15. Wall-Wieler E, Roos LL, Bolton J, Brownell M, Nickel N, Chateau D. Maternal Mental Health after Custody Loss and Death of a Child: A Retrospective Cohort Study Using Linkable Administrative Data. Can J Psychiatry. 2018;63(5):322-328. doi:10.1177/0706743717738494
  16. Schauberger CW, Borgert AJ, Bearwald B. Continuation in Treatment and Maintenance of Custody of Newborns After Delivery in Women With Opioid Use Disorder. J Addict Med. 2020;14(2):119-125. doi:10.1097/ADM.0000000000000534
  17. Suomi A, Bolton A, Pasalich D. The Prevalence of Post-Traumatic Stress Disorder in Birth Parents in Child Protection Services: Systematic Review and Meta-analysis. Trauma Violence Abuse. Published online November 4, 2021:15248380211048444. doi:10.1177/15248380211048444
  18. Thumath M, Humphreys D, Barlow J, et al. Overdose among mothers: The association between child removal and unintentional drug overdose in a longitudinal cohort of marginalised women in Canada. Int J Drug Policy. 2021;91:102977. doi:10.1016/j.drugpo.2020.102977
  19. American Society of Addiction Medicine. Advancing Racial Justice in Addiction Medicine. Default. Published February 25, 2021. Accessed March 2, 2022.
  20. ASAM. Public Policy Statement on Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids. Published online 2017.
  21. KUNINS HV, BELLIN E, CHAZOTTE C, DU E, ARNSTEN JH. The Effect of Race on Provider Decisions to Test for Illicit Drug Use in the Peripartum Setting. J Womens Health 2002. 2007;16(2):245-255. doi:10.1089/jwh.2006.0070
  22. Chasnoff IJ, Landress HJ, Barrett ME. The Prevalence of Illicit-Drug or Alcohol Use during Pregnancy and Discrepancies in Mandatory Reporting in Pinellas County, Florida. N Engl J Med. 1990;322(17):1202-1206. doi:10.1056/NEJM199004263221706
  23. Roberts SCM, Nuru-Jeter A. Universal screening for alcohol and drug use and racial disparities in child protective services reporting. J Behav Health Serv Res. 2012;39(1):3-16. doi:10.1007/s11414-011-9247-x
  24. Kokaliari ED, Roy AW, Taylor J. African American perspectives on racial disparities in child removals. Child Abuse Negl. 2019;90:139-148. doi:10.1016/j.chiabu.2018.12.023
  25. Ketteringham ES, Cremer S, Becker C. Healthy Mothers, Healthy Babies: A Reproductive Justice Response to the “Womb-to-Foster-Care Pipeline.” :51.
  26. Peeler M, Gupta M, Melvin P, et al. Racial and Ethnic Disparities in Maternal and Infant Outcomes Among Opioid-Exposed Mother–Infant Dyads in Massachusetts (2017–2019). Am J Public Health. 2020;110(12):1828-1836. doi:10.2105/AJPH.2020.305888
  27. Schiff DM, Work EC, Foley B, et al. Perinatal Opioid Use Disorder Research, Race, and Racism: A Scoping Review. Pediatrics. 2022;149(3):e2021052368. doi:10.1542/peds.2021-052368
  28. Rosenthal EW, Short VL, Cruz Y, et al. Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder. J Subst Abuse Treat. 2021;131:108454. doi:10.1016/j.jsat.2021.108454
  29. Centers for Disease Control and Injury Prevention. Maternal Mortality Rates in the United States, 2020. Published February 22, 2022. Accessed September 4, 2022.
  30. Stevenson AJ. The Pregnancy-Related Mortality Impact of a Total Abortion Ban in the United States: A Research Note on Increased Deaths Due to Remaining Pregnant. Demography. 2021;58(6):2019-2028. doi:10.1215/00703370-9585908
  31. Terplan M. Test or Talk: Empiric Bias and Epistemic Injustice. Obstet Gynecol. 2022;140(2):150-152. doi:10.1097/AOG.0000000000004884
  32. Baxter L, Brown L, Pating D, et al. Appropriate Use of Drug Testing in Clinical Addiction Medicine. Published online 2017:56.
  33. Koenigs KJ, Chou JH, Cohen S, et al. Informed consent is poorly documented when obtaining toxicology testing at delivery in a Massachusetts cohort. Am J Obstet Gynecol MFM. 2022;4(4):100621. doi:10.1016/j.ajogmf.2022.100621
  34. Faherty LJ, Kranz AM, Russell-Fritch J, Patrick SW, Cantor J, Stein BD. Association of Punitive and Reporting State Policies Related to Substance Use in Pregnancy With Rates of Neonatal Abstinence Syndrome. JAMA Netw Open. 2019;2(11):e1914078. doi:10.1001/jamanetworkopen.2019.14078
  35. Kozhimannil KB, Dowd WN, Ali MM, Novak P, Chen J. Substance use disorder treatment admissions and state-level prenatal substance use policies: Evidence from a national treatment database. Addict Behav. 2019;90:272-277. doi:10.1016/j.addbeh.2018.11.019
  36. Burton AO, Montauban A. Toward Community Control of Child Welfare Funding: Repeal the Child Abuse Prevention and Treatment Act and Delink Child Protection From Family Well-Being. Published online June 1, 2021. Accessed August 18, 2022.
  37. Child Welfare Information Gateway. About CAPTA: A Legislative History. Published online February 2019.
  38. National Advocates for Pregnant Women. Understanding CAPTA and State Obligations. Published online October 2020.
  39. Child Abuse Prevention and Treatment Act §106, 42 U.S.C. § 5106a(b)(2)(B)(ii).
  40. Child Abuse Prevention and Treatment Act §106, 42 U.S.C. § 5106a(b)(2)(B)(iii).
  41. Lloyd Sieger MH, Nichols C, Chasnoff IJ. Child Abuse Prevention and Treatment Act, family care plans and infants with prenatal substance exposure: Theoretical framework and directions for future research. Infant Child Dev. 2022;31(3):e2309. doi:10.1002/icd.2309
  42. Lloyd Sieger MH, Rebbe R. Variation in States’ Implementation of CAPTA’s Substance-Exposed Infants Mandates: A Policy Diffusion Analysis. Child Maltreat. 2020;25(4):457-467. doi:10.1177/1077559520922313
  43. Rosinsky K, Williams S, Fischer M, Haas M. Child Welfare Financing SFY 2018: A survey of federal, state, and local expenditures. Published online March 2021.
  44. Wakeman S, Bryant A, Harrison N. Redefining Child Protection: Addressing the Harms of Structu... : Obstetrics & Gynecology. Accessed July 12, 2022.
  45. Martin M, Snyder HR, Otway G, Holpit L, Day LW, Seidman D. In-hospital Substance Use Policies: An Opportunity to Advance Equity, Reduce Stigma, and Offer Evidence-based Addiction Care. J Addict Med. Published online 2022:10.1097/ADM.0000000000001046. doi:10.1097/ADM.0000000000001046
  46. Patrick SW, Schiff DM, COMMITTEE ON SUBSTANCE USE AND PREVENTION. A Public Health Response to Opioid Use in Pregnancy. Pediatrics. 2017;139(3):e20164070. doi:10.1542/peds.2016-4070
  47. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S):1-91. doi:10.1097/ADM.0000000000000633
  48. Office of the Assistant Secretary for Planning and Evaluation USD of H and HS. Medication-Assisted Treatment for Opioid Use Disorder in the Child Welfare Context: Challenges and Opportunities. Published online November 2018.
  49. Academy of Perinatal Harm Reduction. Academy of Perinatal Harm Reduction. Accessed August 1, 2022.
  50. National Harm Reduction Coalition. Pregnancy and Substance Use: A Harm Reduction Toolkit. National Harm Reduction Coalition. Accessed August 4, 2022.
  51. Wright TE, Schuetter R, Fombonne E, Stephenson J, Haning WF. Implementation and evaluation of a harm-reduction model for clinical care of substance using pregnant women. Harm Reduct J. 2012;9(1):5. doi:10.1186/1477-7517-9-5
  52. Doula Care Saves Lives, Improves Equity, And Empowers Mothers. State Medicaid Programs Should Pay For It | Health Affairs Forefront. Accessed August 19, 2022.
  53. Gannon M, Short V, Becker M, et al. Doula engagement and maternal opioid use disorder (OUD): Experiences of women in OUD recovery during the perinatal period. Midwifery. 2022;106:103243. doi:10.1016/j.midw.2021.103243
  54. Barlow A, Mullany B, Neault N, et al. Effect of a paraprofessional home-visiting intervention on American Indian teen mothers’ and infants’ behavioral risks: a randomized controlled trial. Am J Psychiatry. 2013;170(1):83-93. doi:10.1176/appi.ajp.2012.12010121
  55. Barlow A, Mullany B, Neault N, et al. Paraprofessional-delivered home-visiting intervention for American Indian teen mothers and children: 3-year outcomes from a randomized controlled trial. Am J Psychiatry. 2015;172(2):154-162. doi:10.1176/appi.ajp.2014.14030332
  56. Meinhofer A, Hinde JM, Ali MM. Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings. J Subst Abuse Treat. 2020;110:9-17. doi:10.1016/j.jsat.2019.12.005
  57. Feder KA, Mojtabai R, Musci RJ, Letourneau EJ. U.S. adults with opioid use disorder living with children: Treatment use and barriers to care. J Subst Abuse Treat. 2018;93:31-37. doi:10.1016/j.jsat.2018.07.011
  58. Warshaw C, Lyon ME, Patricia P, Bl J, Phillips H, Hooper MM. Mental Health and Substance Use Coercion Surveys. Published online 2014.
  59. Substance Use Disorder Hurts Moms & Babies. Accessed August 1, 2022.
  60. Patrick SW, Richards MR, Dupont WD, et al. Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder. JAMA Netw Open. 2020;3(8):e2013456. doi:10.1001/jamanetworkopen.2020.13456
  61. Wilder C, Lewis D, Winhusen T. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend. 2015;149:225-231. doi:10.1016/j.drugalcdep.2015.02.012
  62. Schiff DM, Nielsen T, Terplan M, et al. Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. Obstet Gynecol. 2018;132(2):466-474. doi:10.1097/AOG.0000000000002734
  63. Jul 28 P, 2022. Medicaid Postpartum Coverage Extension Tracker. KFF. Published July 28, 2022. Accessed August 1, 2022.
  64. SAMHSA, N-SSATS. National Survey of Substance Abuse Treatment Services (N-SSATS): 2020 | CBHSQ Data. Published 2020. Accessed October 24, 2021.
  65. Clarke JG, Simon RE. Shackling and Separation: Motherhood in Prison. AMA J Ethics. 2013;15(9):779-785. doi:10.1001/virtualmentor.2013.15.9.pfor2-1309
  66. Sussman D. Bound by Injustice: Challenging the Use of Shackles on Incarcerated Pregnant Women. Cardozo J Law Gend. 2008;15(3):477-502.
  67. DOJ. The Americans with Disabilities Act and the Opioid Crisis: Combating Discrimination Against People in Treatment or Recovery. Published online 2022.
  68. Knittel AK, Swartzwelder RA, Zarnick S, et al. Medications for opioid use disorder during pregnancy: Access and continuity in a state women’s prison facility, 2016-2019. Drug Alcohol Depend. 2022;232:109308. doi:10.1016/j.drugalcdep.2022.109308
  69. Pesce v. Coppinger, 355 F. Supp. 3d 35. Accessed September 11, 2022.
  70. Akin Gump Strauss Hauer & Feld, LLP. A Legal Right to Access to Medications for the Treatment of Opioid Use Disorder in the Criminal Justice System. Published online December 2018:9.
  71. Smith v. Aroostook County, No. 19-1340 (1st Cir. 2019). Justia Law. Accessed September 22, 2022.
  72. Sufrin C, Kramer CT, Terplan M, et al. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails. JAMA Netw Open. 2022;5(1):e2144369. doi:10.1001/jamanetworkopen.2021.44369
  73. Winett J. The Persistent Criminalization of Pregnant People Who Use Drugs. Network for Public Health Law. Published September 16, 2022. Accessed September 22, 2022.
  74. Heil SH, Jones HE, Arria A, et al. Unintended Pregnancy in Opioid-abusing Women. J Subst Abuse Treat. 2011;40(2):199-202. doi:10.1016/j.jsat.2010.08.011
  75. Substance Use During Pregnancy. Guttmacher Institute. Published March 14, 2016. Accessed August 2, 2022.
  76. LaBelle R, Weizman S, Canzater S. Statement on Abortion Access for People with Substance Use Disorder. O’Neill. Accessed July 11, 2022.
  77. Bedard R. When the Clinic Becomes Part of the Carceral State. Jewish Currents. Published June 7, 2022. Accessed August 1, 2022.
  78. Quandt KR, Wang L. Recent studies shed light on what reproductive “choice” looks like in prisons and jails. Published December 8, 2021. Accessed September 22, 2022.
  79. Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol. 2019;221(1):B5-B28. doi:10.1016/j.ajog.2019.03.022
  80. Chasnoff IJ, Barber G, Brook J, Akin B. Child Abuse Prevention and Treatment Act: Knowledge of Health Care and Legal Professionals. Published online 2018.
  81. Philips H, Schaeffer S, White-Domain R, Warshaw C. Saving Lives: Meeting the Needs of Intimate Partner Violence Survivors Who Use Opioids. Published online May 2019.
  82. Extend Postpartum Medicaid Coverage. Accessed August 1, 2022.
  83. Affording Housing Models and Recovery. Accessed September 14, 2022.
  84. Program Requirements and FAQs and Applications. Accessed August 1, 2022.
  85. Kroelinger CD. State Strategies to Address Opioid Use Disorder Among Pregnant and Postpartum Women and Infants Prenatally Exposed to Substances, Including Infants with Neonatal Abstinence Syndrome. MMWR Morb Mortal Wkly Rep. 2019;68. doi:10.15585/mmwr.mm6836a1
  86. Krans EE, Campopiano M, Cleveland LM, et al. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Care for Women With Opioid Use Disorder. Obstet Gynecol. 2019;134(2):365-375. doi:10.1097/AOG.0000000000003381
  87. Family Services Programs. Department of Corrections and Community Supervision. Accessed August 18, 2022.
  88. American Society of Addiction Medicine. ASAM Joins ACOG, AMA, and Other Health Care Organizations in Joint Statement in Opposition to Legislative Interference. Default. Published July 7, 2022. Accessed September 12, 2022.